All times are listed in CEST (Central European Summer Time)
Displaying One Session
Industry Satellite Symposium
Date
14.09.2020
Chairs
- Ghassan K. Abou-Alfa (New York, NY, United States of America)
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Industry Satellite Symposium
Welcome and introduction (ID 5306)
Speakers
- Ghassan K. Abou-Alfa (New York, NY, United States of America)
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Industry Satellite Symposium
Brief overview of immuno-oncology in HCC (ID 5307)
Speakers
- Ghassan K. Abou-Alfa (New York, NY, United States of America)
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Industry Satellite Symposium
IO combinations in first-line advanced HCC: Current evidence and ongoing trials (ID 5308)
Speakers
- Peter R. Galle (Mainz, Germany)
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Industry Satellite Symposium
IO combinations early or intermediate-stage HCC: Current evidence and ongoing trials (ID 5311)
Speakers
- Ghassan K. Abou-Alfa (New York, NY, United States of America)
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Industry Satellite Symposium
Putting it all together: Case discussions (ID 5309)
Speakers
- Bruno Sangro (Pamplona, Spain)
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Industry Satellite Symposium
Summary, final thoughts, and audience question and answer session (ID 5310)
Speakers
- Ghassan K. Abou-Alfa (New York, NY, United States of America)
AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma
Industry Satellite Symposium
Live Q&A - 18 September 2020 - 15:30-16:00 (ID 5497)
Speakers
- Ghassan K. Abou-Alfa (New York, NY, United States of America)